PRESS-RELEASE ·Filed Mar 16, 2026
Press release · Earnings
Actionable Insight • Neutral
Await full financial disclosure in the upcoming 8-K or 10-K filing. Lack of data in this release limits trading relevance.
Final — all horizons settled through T+60d ⚠ clustered
CUE ▲ +273.04% at T+60d
NEUTRAL call +273.04% · α vs SPY +263.18% · entry $8.16 → $30.44
T+1d
-2.94%
call -2.94% · α -1.54%
$7.92
settled 7mo ago
T+5d
-6.25%
call -6.25% · α -3.60%
$7.65
settled 7mo ago
T+20d
+166.18%
call +166.18% · α +161.88%
$21.72
settled 7mo ago
T+60d
+273.04%
call +273.04% · α +263.18%
$30.44
settled 5mo ago
Price Chart
Loading chart...
Executive Summary
Cue Biopharma reported its fourth quarter and full year 2025 financial results. The press release announces financial results but contains no actual financial figures, metrics, or guidance, limiting actionable insights.
Key Facts
- Cue Biopharma issued a press release announcing its Q4 and full year 2025 financial results.
- No revenue, EPS, cash burn, or guidance figures were disclosed in the provided text.
- Company remains in clinical-stage development with no commercial products.
Financial Impact
Insufficient data — no financial metrics disclosed
Risk Factors
- Extremely low market cap ($26M) increases volatility and risk of dilution
- No revenue-generating products; dependent on clinical progress and financing
Market Snapshot
Exchange
Nasdaq
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3256701 |
25 reports for CUE
69% Hit rate @ T+1 Went positive at some point 10 of 13 best @ T+20▲ +519.50%
Filters
Rows
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 14, 2026 12d ago | Insider Cluster | $18.67 $16.71 | ▲ +10.50% | ▲ +9.39% | $18.45 (+1.18%) |
Oct 13, 2026 13d ago | 144 | $18.60 $18.67 | ▲ +0.38% | ▲ +0.09% | $18.45 (−0.81%) |
Oct 8, 2026 18d ago | SC 13G/A | $22.33 $27.66 | ▲ +23.87% | ▲ +23.27% | $18.45 (−17.38%) |
Sep 21, 2026 5w ago | 8-K | $28.27 $30.90 | ▲ +9.30% | ▲ +9.32% | $18.45 (−34.74%) |
Sep 20, 2026 5w ago | Press Release | $28.27 $30.90 | ▲ +9.30% | ▲ +9.32% | $18.45 (−34.74%) |
Aug 21, 2026 9w ago | EFFECT | $23.98 $23.18 | ▲ +3.34% | ▲ +3.04% | $18.45 (+23.06%) |
Aug 17, 2026 10w ago | Insider Cluster | $25.70 $26.28 | ▼ −2.26% | ▼ −2.05% | $18.45 (+28.21%) |
Aug 14, 2026 10w ago | Press Release | $27.64 $25.70 | ▼ −7.02% | ▼ −6.34% | $18.45 (−33.25%) |
Aug 13, 2026 10w ago | 144 | $34.20 $27.64 | ▼ −19.18% | ▼ −18.71% | $18.45 (−46.05%) |
Jul 9, 2026 15w ago | Press Release | $36.78 $30.92 | ▼ −15.93% | ▼ −15.17% | $18.45 (−49.84%) |
Showing 10 of 25
US Market Status
Market Closed — Opens in 4h 19m
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers